These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 23444510

  • 1. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
    Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
    [Abstract] [Full Text] [Related]

  • 2. Choice of first-line treatment for metastatic prostate cancer.
    Prescrire Int; 2013 Feb; 22(135):51. PubMed ID: 23444511
    [No Abstract] [Full Text] [Related]

  • 3. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [Abstract] [Full Text] [Related]

  • 4. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.
    Cochrane Database Syst Rev; 2014 Jun 30; 2014(6):CD009266. PubMed ID: 24979481
    [Abstract] [Full Text] [Related]

  • 5. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.
    Evid Rep Technol Assess (Summ); 1999 May 30; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [Abstract] [Full Text] [Related]

  • 6. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov 30; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 7. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 30; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 8. Second-line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief.
    Prescrire Int; 2013 Mar 30; 22(136):74-8. PubMed ID: 23593699
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE.
    Eur Urol; 1997 Mar 30; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [Abstract] [Full Text] [Related]

  • 11. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F.
    Bull Cancer; 2006 Sep 30; 93(9):949-58. PubMed ID: 16980238
    [Abstract] [Full Text] [Related]

  • 12. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan 30; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 13. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011 Jan 30; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

  • 14. Endocrine prevention and treatment of prostate cancer.
    Tammela TL.
    Mol Cell Endocrinol; 2012 Sep 05; 360(1-2):59-67. PubMed ID: 22465099
    [Abstract] [Full Text] [Related]

  • 15. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS, Pitts WR.
    J Urol; 2003 Nov 05; 170(5):1703-8. PubMed ID: 14532759
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct 05; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

  • 17. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE.
    Cancer; 1996 May 01; 77(9):1854-61. PubMed ID: 8646685
    [Abstract] [Full Text] [Related]

  • 18. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
    DeAntoni E, Crawford ED.
    Urologe A; 1995 Sep 01; 34(5):382-8. PubMed ID: 7483154
    [Abstract] [Full Text] [Related]

  • 19. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT.
    Urology; 1995 Dec 01; 46(6):849-55. PubMed ID: 7502428
    [Abstract] [Full Text] [Related]

  • 20. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.